|Bid||43.80 x 900|
|Ask||43.82 x 1100|
|Day's Range||43.79 - 43.98|
|52 Week Range||39.48 - 45.62|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||22.60|
|Forward Dividend & Yield||1.74 (3.94%)|
|1y Target Est||52.00|
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
Sanofi on Wednesday said a reorganisation of its research and development operation in Germany and France would result in 466 job cuts in the two countries. In an emailed statement, a spokesman with the French drugmaker said the reshuffle aimed at enabling Sanofi to concentrate its research efforts in cancer, immunology, rare diseases and vaccines. The 466 job cuts are to be implemented on a voluntary basis, Sanofi said.
Sanofi SA (NASDAQ: SNY ) and Alphabet Inc (NASDAQ: GOOG ) (NASDAQ: GOOGL ) said Tuesday they have joined forces to launch a virtual Innovation lab with the aim of transforming how medicine and health services ...
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Trump Promises Mass Roundup of Millions of Undocumented Immigrants The low-end of the US economy could be on the verge of a serious conflagration. United States President Donald Trump has promised, via tweet as is his wont, that ICE agents will start “removing the millions of illegal aliens who have illicitly found their way into […]The post Market Morning: Trump Immigrant Roundup, Gold Threatens, Google Goes Pharma appeared first on Market Exclusive.
French healthcare company Sanofi has teamed up with Google to work on innovations, aimed at using emerging data technologies to change how medicines and health services will be delivered in future. Sanofi and Google will use data sets to improve their understanding of key diseases and extract patients' insights and feedback, the companies said in a joint statement. "Combining Sanofi's biologic innovations and scientific data with Google's industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies," said Ameet Nathwani, chief medical officer and executive vice-president, Sanofi.
(Bloomberg) -- Alphabet Inc.’s Google will bring its artificial-intelligence and cloud-computing capabilities to a new partnership with pharma giant Sanofi.The project is aimed at accelerating the discovery of new medicines, increasing the understanding of what treatments work for patients and making Sanofi’s operations more efficient, the Paris-based drugmaker said in a statement Tuesday. The companies didn’t provide financial details.The pact is the latest sign of increasing collaboration between the technology and health-care industries. Pharma companies like Sanofi are teaming up with AI specialists, hiring data scientists or even snapping up tech startups in a bid to become faster and more efficient as costs rise.The new partnership will allow Sanofi to come up with more personalized approaches to treatment, the company said. The drugmaker and Google also plan to apply artificial intelligence to forecast sales and improve marketing and supply efforts.To contact the reporter on this story: James Paton in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Eric Pfanner at email@example.com, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Healthcare was slow to benefit from digitalisation. Heavy regulations, pricing power and a history of failed IT projects were to blame. Tuesday’s tie-up between Google and French drugmaker Sanofi to create a “virtual innovation lab” is the latest example.
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
TORONTO , June 11, 2019 /CNW Telbec/ - The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.
With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.